A Phase 3 interventional study of MEDI8897 and Placebo in Respiratory Syncytial Virus Infections, sponsored by AstraZeneca. Completed at 199 sites in 31 countries. Open to participants aged 0 Years to 1 Year, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-28.
Sponsored by AstraZeneca · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca — none open to participants now, none under way, none of them phase 3. Respiratory Syncytial Virus Infections · AstraZeneca.
Among the 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca, this one is the 2nd largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2019, is one of 3 in phase 3, and was the 12th registered.
306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.
Browse Respiratory Syncytial Virus Infections studies →None of the 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca is open now. The open studies under Respiratory Syncytial Virus Infections, anywhere →
Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.
This study: 0 Years to 1 Year · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 4
First in 2003; this study’s year is marked. 2 started in 2019.
This study's enrollment of 3,012 is above the median of 89 across 223 interventional studies indexed under Respiratory Syncytial Virus Infections.
Median enrollment 239 across the 12 interventional studies, 233 across the 2 observational. Of the 14 that completed or were terminated, 10 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and antidrug antibody (ADA) response for MEDI8897 in healthy late preterm and term infants who are 35 weeks or greater gestational age and entering their first RSV season.
This pivotal Phase 3 study will determine if MEDI8897 will prevent medically attended RSV-confirmed lower respiratory tract infections (LRTI) in healthy infants entering their first RSV season. The population to be enrolled is healthy late preterm and term infants born 35 weeks 0 days or greater gestational age (GA) who would not be eligible to receive RSV prophylaxis. A total of approximately 3,000 infants will be randomized 2:1 to receive either MEDI8897 or placebo. All subjects will be followed for approximately 510 days after dosing. Enrollment is planned at approximately 350 sites across the USA, Canada, Europe, Asia, and Southern Hemisphere.
Key Inclusion Criteria:
Key Exclusion Criteria:
Anti-RSV monoclonal antibody with an extended half-life
Drug: MEDI8897
Commercially available 0.9% (w/v) saline
Drug: Placebo
Anti-RSV monoclonal antibody with an extended half-life
Commercially available 0.9% (w/v) saline
Number of Participants With MA RSV LRTI Through 150 Days Post Dose (Primary Cohort)
Primary Endpoint Analysed on Primary Cohort Through 150 Days (N=1490 Participants)
Time frame: Through 150 Days Post Dose
Number of Participants With MA RSV LRTI With Hospitalisation Through 150 Days Post Dose (Primary Cohort)
Hospitalization Analysed on Primary Cohort Through 150 Days (N=1490 Participants)
Time frame: Through 150 Days Post Dose
Summary of Serum Concentrations (ug/mL) of MEDI8897 by Group
Number of Subjects with at Least one Assessment
Time frame: By visit until day 360 post dose
Anti-drug Antibody Results by Visit (As Treated Population)
Number of subjects with a positive result and a valid titer result at the specific visit
Time frame: From baseline to 360 day post dose visit
Number of Participants With MA RSV LRTI Through 150 Days Post Dose (All Subjects)
Primary Endpoint Analysed on All Subjects Through 150 Days (N=3012 participants)
Time frame: Through 150 Days Post Dose
Number of Participants With MA RSV LRTI With Hospitalisation Through 150 Days Post Dose (All Subjects)
Hospitalization Analysed on All Subjects Through 150 Days (N=3012 participants)
Time frame: Through 150 Days Post Dose
Number of Participants With Disease From the 2nd RSV Season (All Subjects)
Time frame: From Day 361 to Day 510 Post Dose
First Subject In: 23-07-2019. Last Subject Last Visit: 21-03-2023. The study was planned to analyze data on the full enrolment of approximately 3000 infants. The impact of the COVID-19 pandemic on RSV circulation led to the decision to analyze the primary endpoint based on the first 1500 subjects enrolled (Primary Cohort). After the COVID-19 pandemic the study restarted. So the study comprised 2 cohorts: a Primary and a Safety for a total of 3319 screened subjects.
| Milestone | Placebo | Medi8897 |
|---|---|---|
| Started | 496 | 994 |
| Completed day 151 follow up | 488 | 977 |
| Completed day 361 follow up | 453 | 914 |
| Treated participants | 491 | 994 |
| Completed | 43 | 89 |
| Not completed | 453 | 905 |
| Withdrew: Lost to follow-up | 3 | 9 |
| Withdrew: Any other reason | 3 | 4 |
| Withdrew: Death | 0 | 4 |
| Withdrew: Withdrawal by subject | 14 | 20 |
| Withdrew: Covid-19 pandemic | 1 | 3 |
| Withdrew: Ongoing at the dco date | 432 | 865 |
| Milestone | Placebo | Medi8897 |
|---|---|---|
| Started | 1003 | 2009 |
| Completed day 151 follow up | 985 | 1977 |
| Completed day 361 follow up | 967 | 1944 |
| Treated participants | 997 | 1997 |
| Completed | 923 | 1873 |
| Not completed | 80 | 136 |
| Withdrew: Any other reason | 16 | 23 |
| Withdrew: Covid-19 | 1 | 3 |
| Withdrew: Withdrawal by subject | 35 | 44 |
| Withdrew: Death | 0 | 5 |
| Withdrew: Lost to follow-up | 28 | 61 |
Hospitalization Analysed on Primary Cohort Through 150 Days (N=1490 Participants)
| Participants | Placebo | Medi8897 |
|---|---|---|
| Observed events through day 150 post dose | 8 | 6 |
| Subjects requiring imputation (subjects without events and not followed through 150 days post dose) | 6 | 15 |
| Subjects without event through day 150 post dose | 482 | 973 |
Primary Endpoint Analysed on Primary Cohort Through 150 Days (N=1490 Participants)
| Participants | Placebo | Medi8897 |
|---|---|---|
| Observed events through day 150 post dose | 25 | 12 |
| Subjects requiring imputation (Subjects without events and not followed through 150 days post dose) | 6 | 15 |
| Subjects without event through day 150 post dose | 465 | 967 |
Primary Endpoint Analysed on All Subjects Through 150 Days (N=3012 participants)
| Participants | Placebo | Medi8897 |
|---|---|---|
| Observed events through day 150 post dose | 54 | 24 |
| Subjects requiring imputation (Subjects without events and not followed through 150 days post dose) | 17 | 31 |
| Subjects without event through day 150 post dose | 932 | 1954 |
Hospitalization Analysed on All Subjects Through 150 Days (N=3012 participants)
| Participants | Placebo | Medi8897 |
|---|---|---|
| Observed events through day 150 post dose | 20 | 9 |
| Subjects requiring imputation (Subjects without events and not followed through 150 days post dose) | 18 | 31 |
| Subjects without event through day 150 post dose | 965 | 1969 |
| Participants | Placebo | Medi8897 |
|---|---|---|
| MA RSV LRTI (protocol defined) | 10 | 19 |
| MA RSV LRTI hospitalisation (protocol defined) | 3 | 3 |
Number of Subjects with at Least one Assessment
| ug/mL | Medi8897, 50 mg | Medi8897, 100 mg |
|---|---|---|
| Day 7 Post Dose | 89.91 ± 39.3 | 164.03 ± 15.8 |
| Day 14 Post Dose | 74.09 ± 124.9 | 105.05 ± 89.2 |
| Day 30 Post Dose | 68.63 ± 58.6 | 100.54 ± 90.1 |
| Day 150 Post Dose | 18.32 ± 63.1 | 27.73 ± 62.9 |
| Day 360 Post Dose | 1.75 ± 76.7 | 2.86 ± 85.7 |
Number of subjects with a positive result and a valid titer result at the specific visit
| Participants | Placebo | Medi8897 |
|---|---|---|
| Baseline | 4 | 4 |
| Day 30 Post Dose | 2 | 14 |
| Day 150 Post Dose | 1 | 21 |
| Day 360 Post Dose | 10 | 81 |
Collected over All-Cause Mortality monitored/assessed up to 510 days post dose . Adverse Events monitored/assessed up to day 360 post dose.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/997 (0%) | 83/997 (8.3%) | 836/997 (83.9%) |
| MEDI8897 | 5/1,997 (0.3%) | 149/1,997 (7.5%) | 1,717/1,997 (86%) |
| Event | Placebo | MEDI8897 |
|---|---|---|
| BronchiolitisInfections and infestations | 17/997 | 27/1997 |
| Respiratory syncytial virus bronchiolitisInfections and infestations | 10/997 | 5/1997 |
| GastroenteritisInfections and infestations | 5/997 | 14/1997 |
| PneumoniaInfections and infestations | 5/997 | 13/1997 |
| Urinary tract infectionInfections and infestations | 5/997 | 7/1997 |
| BronchitisInfections and infestations | 4/997 | 3/1997 |
| LaryngitisInfections and infestations | 3/997 | 3/1997 |
| PyrexiaGeneral disorders | 1/997 | 6/1997 |
| Lower respiratory tract infectionInfections and infestations | 0/997 | 6/1997 |
| Covid-19Infections and infestations | 2/997 | 3/1997 |
| Event | Placebo | MEDI8897 |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 316/997 | 639/1997 |
| NasopharyngitisInfections and infestations | 237/997 | 441/1997 |
| PyrexiaGeneral disorders | 122/997 | 290/1997 |
| Dermatitis diaperSkin and subcutaneous tissue disorders | 103/997 | 224/1997 |
| RhinitisInfections and infestations | 102/997 | 201/1997 |
| GastroenteritisInfections and infestations | 100/997 | 202/1997 |
| DiarrhoeaGastrointestinal disorders | 89/997 | 171/1997 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 86/997 | 164/1997 |
| Otitis mediaInfections and infestations | 76/997 | 154/1997 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 65/997 | 152/1997 |
These are the Overall Number of All Subjects Population
| Age, Continuous(Months) | Placebo | Medi8897 | Total |
|---|---|---|---|
| Age (months) in Primary Cohort | 3.012 ± 2.2520 | 2.912 ± 2.2099 | 2.946 ± 2.2237 |
| Age (months) in All Subjects | 2.918 ± 2.2740 | 2.905 ± 2.220 | 2.909 ± 2.2376 |
| Sex: Female, Male(Participants) | Placebo | Medi8897 | Total |
|---|---|---|---|
| Sex in Primary Cohort — Female | 257 | 464 | 721 |
| Sex in Primary Cohort — Male | 239 | 530 | 769 |
| Sex in All Subjects — Female | 500 | 938 | 1438 |
| Sex in All Subjects — Male | 503 | 1071 | 1574 |
| Race/Ethnicity, Customized(Participants) | Placebo | Medi8897 | Total |
|---|---|---|---|
| Race in Primary Cohort — American Indian or Alaska Native | 26 | 57 | 83 |
| Race in Primary Cohort — Asian | 18 | 36 | 54 |
| Race in Primary Cohort — Black or African American | 136 | 286 | 422 |
| Race in Primary Cohort — Native Hawaiian or other Pacific Islander | 5 | 6 | 11 |
| Race in Primary Cohort — White | 272 | 524 | 796 |
| Race in Primary Cohort — Multiple categories checked | 1 | 12 | 13 |
| Race in Primary Cohort — Other | 38 | 70 | 108 |
| Race in Primary Cohort — Missing | 0 | 3 | 3 |
| Race in All Subjects — American Indian or Alaska Native | 52 | 92 | 144 |
| Race in All Subjects — Asian | 50 | 109 | 159 |
| Race in All Subjects — Black or African American | 138 | 299 | 437 |
| Race in All Subjects — Native Hawaiian or other Pacific Islander | 8 | 15 | 23 |
| Race in All Subjects — White | 541 | 1052 | 1593 |
| Race in All Subjects — Multiple categories checked | 8 | 19 | 27 |
| Race in All Subjects — Other | 206 | 420 | 626 |
| Race in All Subjects — Missing | 0 | 3 | 3 |
Showing the first 100 of 199 sites across 31 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Jul 2019 to primary completion in Mar 2021, 19 months.
Results were first posted in Feb 2024, 2 years 11 months after primary completion. A results delay was requested in Feb 2022.
Of 27 industry-sponsored phase 3 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 19. This study's 19 months is above that.
Counting every sponsor, half of 32 studies reached it within 8 months; a quarter within 6 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nirsevimab
Respiratory Syncytial Virus Infections →